Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration

Ophthalmology

Volumn 122, Issue 4, 2015, Pages 822-832

  Schmidt Erfurth, Ursula ^a   Waldstein, Sebastian M ^a   Deak, Gabor Gyoergy ^a   Kundi, Michael ^a   Simader, Christian ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; ANTIANGIOGENIC THERAPY; ARTICLE; CENTRAL RETINAL THICKNESS; CONTROLLED STUDY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; OPTICAL COHERENCE TOMOGRAPHY DEVICE; POST HOC ANALYSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETINA DEGENERATION; RETINA DETACHMENT; SUBRETINAL FLUID; THERAPY EFFECT; TREATMENT OUTCOME; VISION; VISUAL ACUITY; VISUAL IMPAIRMENT; AGED; ANTAGONISTS AND INHIBITORS; BLINDNESS; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; FEMALE; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MALE; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; PHYSIOLOGY; PIGMENT EPITHELIUM; RETINAL DETACHMENT; VERY ELDERLY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BLINDNESS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINAL DETACHMENT; RETINAL PIGMENT EPITHELIUM; SUBRETINAL FLUID; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84925373614     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2014.11.017     Document Type: Article

References (41)

1. W. Smith, J. Assink, and R. Klein Risk factors for age-related macular degeneration: pooled findings from three continents Ophthalmology 108 2001 697 704
2. R. Kawasaki, M. Yasuda, and S.J. Song The prevalence of age-related macular degeneration in Asians: a systematic review and meta-analysis Ophthalmology 117 2010 921 927
3. D.S. Friedman, B.J. O'Colmain, and B. Munoz Prevalence of age-related macular degeneration in the United States Arch Ophthalmol 122 2004 564 572
4. J.M. Seddon, W.C. Willett, and F.E. Speizer A prospective study of cigarette smoking and age-related macular degeneration in women JAMA 276 1996 1141 1146
5. J.M. Seddon, J. Cote, and N. Davis Progression of age-related macular degeneration: association with body mass index, waist circumference, and waist-hip ratio Arch Ophthalmol 121 2003 785 792
6. T. Vos, A.D. Flaxman, and M. Naghavi Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010 Lancet 380 2012 2163 2196
7. P.H. Miskala, E.B. Bass, and N.M. Bressler Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: quality-of-life findings: SST report no. 12 Ophthalmology 111 2004 1981 1992
8. K. Spilsbury, K.L. Garrett, and W.Y. Shen Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization Am J Pathol 157 2000 135 144
9. M.G. Krzystolik, M.A. Afshari, and A.P. Adamis Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment Arch Ophthalmol 120 2002 338 346
10. N. Ferrara, R.D. Mass, and C. Campa Targeting VEGF-A to treat cancer and age-related macular degeneration Annu Rev Med 58 2007 491 504
11. P.J. Rosenfeld, D.M. Brown, and J.S. Heier Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431
12. D.M. Brown, P.K. Kaiser, and M. Michels Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 2006 1432 1444
13. D.B. Rein, J.S. Wittenborn, and X. Zhang Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments Arch Ophthalmol 127 2009 533 540
14. J.P. Campbell, S.B. Bressler, and N.M. Bressler Impact of availability of anti-vascular endothelial growth factor therapy on visual impairment and blindness due to neovascular age-related macular degeneration Arch Ophthalmol 130 2012 794 795
15. S.Y. Cohen, G. Mimoun, and H. Oubraham Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study Retina 33 2013 474 481
16. C.D. Regillo, D.M. Brown, and P. Abraham Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1 Am J Ophthalmol 145 2008 239 248.e5
17. U. Schmidt-Erfurth, B. Eldem, and R. Guymer Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study Ophthalmology 118 2011 831 839
18. F.G. Holz, W. Amoaku, and J. Donate Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study Ophthalmology 118 2011 663 671
19. G.A. Lalwani, P.J. Rosenfeld, and A.E. Fung A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study Am J Ophthalmol 148 2009 43 58
20. D.F. Martin, M.G. Maguire, and S.L. Fine Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results Ophthalmology 119 2012 1388 1398
21. N. Hawkes Avastin is as effective as Lucentis for wet AMD and could save NHS 84m pound a year, study shows BMJ 344 2012 3275
22. U. Chakravarthy, S.P. Harding, and C.A. Rogers Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial Ophthalmology 119 2012 1399 1411
23. J.S. Heier, D.M. Brown, and V. Chong Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration Ophthalmology 119 2012 2537 2548
24. U. Schmidt-Erfurth, P.K. Kaiser, and J.F. Korobelnik Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies Ophthalmology 121 2014 193 201
25. C. Simader, M. Ritter, and M. Bolz Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration Ophthalmology 121 2014 1237 1245
26. M. Ritter, J. Elledge, and C. Simader Evaluation of optical coherence tomography findings in age-related macular degeneration: a reproducibility study of two independent reading centres Br J Ophthalmol 95 2011 381 385
27. W. Geitzenauer, C.K. Hitzenberger, and U.M. Schmidt-Erfurth Retinal optical coherence tomography: past, present and future perspectives Br J Ophthalmol 95 2011 171 177
28. P.A. Keane, P.J. Patel, and S. Liakopoulos Evaluation of age-related macular degeneration with optical coherence tomography Surv Ophthalmol 57 2012 389 414
29. A.E. Fung, G.A. Lalwani, and P.J. Rosenfeld An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration Am J Ophthalmol 143 2007 566 583
30. G.J. Jaffe, D.F. Martin, and C.A. Toth Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials Ophthalmology 120 2013 1860 1870
31. K.B. Freund, S.A. Zweifel, and M. Engelbert Do we need a new classification for choroidal neovascularization in age-related macular degeneration? Retina 30 2010 1333 1349
32. U. Schmidt-Erfurth, R.A. Leitgeb, and S. Michels Three-dimensional ultrahigh-resolution optical coherence tomography of macular diseases Invest Ophthalmol Vis Sci 46 2005 3393 3402
33. H. Hayashi, K. Yamashiro, and A. Tsujikawa Association between foveal photoreceptor integrity and visual outcome in neovascular age-related macular degeneration Am J Ophthalmol 148 2009 83 89
34. T. Iida, L.A. Yannuzzi, and R.F. Spaide Cystoid macular degeneration in chronic central serous chorioretinopathy Retina 23 2003 1 7
35. F. Sulzbacher, C. Kiss, and A. Kaider Correlation of SD-OCT features and retinal sensitivity in neovascular age-related macular degeneration Invest Ophthalmol Vis Sci 53 2012 6448 6455
36. R.F. Spaide Enhanced depth imaging optical coherence tomography of retinal pigment epithelial detachment in age-related macular degeneration Am J Ophthalmol 147 2009 644 652
37. P.A. Keane, S. Liakopoulos, and S.C. Ongchin Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration Invest. Ophthalmol Vis Sci 49 2008 3115 3120
38. G. Querques, T.H. Tran, and R. Forte Anatomic response of occult choroidal neovascularization to intravitreal ranibizumab: a study by indocyanine green angiography Graefes Arch Clin Exp Ophthalmol 250 2012 479 484
39. A.W. Scott, and S.B. Bressler Retinal angiomatous proliferation or retinal anastomosis to the lesion Eye (Lond) 24 2010 491 496
40. J.J. Jung, C.Y. Chen, and S. Mrejen The incidence of neovascular subtypes in newly diagnosed neovascular age-related macular degeneration Am J Ophthalmol 158 2014 769 779
41. Y.J. Hong, M. Miura, and M.J. Ju Simultaneous investigation of vascular and retinal pigment epithelial pathologies of exudative macular diseases by multifunctional optical coherence tomography Invest Ophthalmol Vis Sci 55 2014 5016 5031